quadraScope invests in biotech companies working to dramatically extend human healthspan by targeting the hallmarks of aging.
Hallmarks of aging
Biogerontology is the new science that aims to extend human healthspan by addressing the biological basis of aging. It revolves around the concept of the Hallmarks of Aging, a framework introduced in 2013 by LĂłpez-OtĂn et al. and further expanded in the paper Hallmarks of Aging: An Expanding Universe in 2023. The hallmarks of aging are shown below.
Genomic instability
Telomere attrition
Epigenetic alterations
Cellular senescence
Mitochondrial dysfunction
Stem cell exhaustion
Deregulated nutrient-sensing
Loss of proteostasis
Disabled macroautophagy
Altered intercellular communication
Chronic inflammation
Dysbiosis
Our portfolio
We have a diverse, synergetic portfolio led by serial entrepreneurs and renowned scientists.
Team
We are a women-led team with a strong track record of taking new ventures from inception to profitable exits, including a 12x exit, and deep understanding of the emerging longevity science and market.
The quadraScope team is focused on the right sector, with the right team to select and vet investment opportunities. The rejuvenation industry is an emerging next wave of biotech technologies that has seen a recent surge in funding while engaging the top scientific talent.Â
Hans Keirstead, PhD
Chairman, Immunis
quadraScope’s investment allowed us to start the development of a biobetter growth hormone. This anchor investment attracted funding from two other major investors.
Robert (Bobby) Brooke
CEO, Intervene Immune
quadraScope has been a sounding board and a strong source of encouragement and support for our strategic direction.
Tom Benson, PhD
CEO, Mitrix Bio
quadraScope is tapping the fast-emerging rejuvenation market with an abundance of research ready to be commercialized. With their strategic locations in Boston and Tel-Aviv they are poised to leverage the high concentration of biotech academia, industry and talent pool.
Reason
CEO, Repair Biotechnologies
We chose to partner with Quadrascope because of the strategic alignment of our visions, namely the importance of investment in programs that extend life-span and health-span while at the same time applying the same science to treat diseases that have no treatment.
Menachem Abraham
CEO, Klogenix
quadraScope, our first investor, has encouraged the formation of rejuvenation clinics and has been active in defining the treatment protocols as a strategic pillar alongside clinical trials.
